A Phase 2 Multicenter, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of Pf-03049423 In Subjects With Ischemic Stroke
Latest Information Update: 03 Jul 2019
Price :
$35 *
At a glance
- Drugs PF 3049423 (Primary)
- Indications Stroke
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 06 May 2014 New trial record